THROMBOLYTIC AGENTS AND ANTICOAGULANTS

被引：8

作者：

BECKER, RC

机构：

[1] Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, 01655, MA

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1993年 / 7卷 / 05期

关键词：

THROMBOLYTICS; ANTICOAGULANTS; THROMBIN; FIBRIN;

D O I：

10.1007/BF00878937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The medical and scientific communities, appreciating the pivotal role of thrombosis in the evolution and expression of atherosclerotic coronary artery disease, have embarked upon intense efforts to develop safe, effective, and affordable thrombolytic agents and anticoagulants. With an understanding that more is not always better, these new compounds, mutants, and derivatives will be designed specifically to impair, neutralize, or enhance several key components of well-characterized thrombotic and fibrinolytic processes. If efforts continue at the current pace, one or more ''designer'' thrombolytics and anticoagulants will be ready for Phase II or Phase III clinical trials in the near future.

引用

页码：825 / 828

页数：4

共 18 条

[1]

AGNELLI G, 1992, THROMB HAEMOSTASIS, V68, P331

[2] ANTICOAGULANT EFFECTS OF HIRULOG, A NOVEL THROMBIN INHIBITOR, IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].

CANNON, CP ;

MARAGANORE, JM ;

LOSCALZO, J ;

MCALLISTER, A ;

EDDINGS, K ;

GEORGE, D ;

SELWYN, AP ;

ADELMAN, B ;

FOX, I ;

BRAUNWALD, E ;

GANZ, P .

AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (10) :778-782

[3] THROMBOLYTIC AND PHARMACOKINETIC PROPERTIES OF CHIMERIC TISSUE-TYPE AND UROKINASE-TYPE PLASMINOGEN ACTIVATORS [J].

COLLEN, D ;

LU, HR ;

LIJNEN, HR ;

NELLES, L ;

STASSEN, JM .

CIRCULATION, 1991, 84 (03) :1216-1234

[4] THROMBOLYTIC AND PHARMACOKINETIC PROPERTIES OF A CONJUGATE OF RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR WITH A MONOCLONAL-ANTIBODY SPECIFIC FOR CROSS-LINKED FIBRIN IN A BABOON VENOUS THROMBOSIS MODEL [J].

COLLEN, D ;

DEWERCHIN, M ;

RAPOLD, HJ ;

LIJNEN, HR ;

STASSEN, JM .

CIRCULATION, 1990, 82 (05) :1744-1753

[5]

COLLEN D, 1991, THROMB HAEMOSTASIS, V65, P174

[6]

EHRLICH H J, 1987, Fibrinolysis, V1, P75, DOI 10.1016/0268-9499(87)90013-0

[7] EFFECTIVE THROMBOLYSIS WITHOUT MARKED PLASMINEMIA AFTER BOLUS INTRAVENOUS ADMINISTRATION OF VAMPIRE BAT SALIVARY PLASMINOGEN-ACTIVATOR IN RABBITS [J].

GARDELL, SJ ;

RAMJIT, DR ;

STABILITO, II ;

FUJITA, T ;

LYNCH, JJ ;

CUCA, GC ;

JAIN, D ;

WANG, SP ;

TUNG, J ;

MARK, GE ;

SHEBUSKI, RJ .

CIRCULATION, 1991, 84 (01) :244-253

[8]

HARE TR, 1992, THROMB HAEMOSTASIS, V68, P165

[9] PREVENTION OF ARTERIAL REOCCLUSION AFTER THROMBOLYSIS WITH RECOMBINANT LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR [J].

HASKEL, EJ ;

TORR, SR ;

DAY, KC ;

PALMIER, MO ;

WUN, TC ;

SOBEL, BE ;

ABENDSCHEIN, DR .

CIRCULATION, 1991, 84 (02) :821-827

[10] EFFECTS OF THROMBIN INHIBITION ON THE DEVELOPMENT OF ACUTE PLATELET-THROMBUS DEPOSITION DURING ANGIOPLASTY IN PIGS - HEPARIN VERSUS RECOMBINANT HIRUDIN, A SPECIFIC THROMBIN INHIBITOR [J].

HERAS, M ;

CHESEBRO, JH ;

PENNY, WJ ;

BAILEY, KR ;

BADIMON, L ;

FUSTER, V .

CIRCULATION, 1989, 79 (03) :657-665

← 1 2 →